Prediction of survival using Super PC. A survival classifier based on 025 + 040 trials was used to identify high- and low-risk groups within an independent test dataset derived from 039 patients. Kaplan-Meier analyses of the actual survival of these predicted high-/low-risk patient groups is shown for test set (A) trial 039 bortezomib, (B) trial 039 Dex, (C) ISS = 1 for patients from 039 trial (bortezomib or Dex), (D) ISS = 2 to 3 for patients from 039 trial (bortezomib or Dex).